In the field of low back pain alone, there have been several recent, high-quality trials showing only small differences in improvements of disability, of questionable clinical significance, between various types of non-pharmacological therapies, or between these and usual primary care [ 21, 25, 29, 32, 34, 35].
Recurrence of pain episodes was a quite common phenomenon in the year after delivery but seems to be independent from the differences in improvement on resumption of normal activities, participation (work) and reduced fears between the both study groups.
Tests of mean differences in improvement on the PRO measures were completed between the two groups.
This pilot study shows that in patients with symptomatic ICA occlusion, oxygen-15 PET did not detect differences in improvement of CBF, CBV or OEF between interventional and standard treatment.
A significant differences in improvement of hematological parameters were observed between the two groups.
The pooled mean differences in improvement of ODI ranged from −1.265 to 6.969, with the pooled mean differences being 1.265.
However, neither unadjusted nor adjusted analyses showed statistically significant differences in improvement of A1C between intervention and control groups at 6 months (Table 2).
Although significantly more patients in arm 2 than in arm 1 had achieved remission at 1 year, we found no significant differences in improvement of functional ability, HRQoL and VAS results between arms.
Multivariate analysis of covariance with group, centre and the baseline covariate as independent variables will be used to estimate differences in improvement of the UDI after 12 months between the groups with 95% confidence intervals.
This pragmatic pilot study provides preliminary data showing clinically and statistically significant differences in improvement of pain and physical functioning between treatment groups, favoring the SMC+CMT group for young, racially diverse adults with low back pain.
For example, among patients taking nortriptyline in GENDEP, genetic variation in the beta-3 subunit of the G-protein complex (GNB3) was associated specifically with differences in improvement of neurovegetative symptoms (that is, symptoms relating to sleep and appetite), but was not associated with improvement in other symptom dimensions (such as observed mood or cognitive symptoms) [ 68].
